Peripheral Blood B Lymphocyte Count and PD-1/PD-L1 Expression in Children with Refractory/Recurrent B-Acute Lympho-blastic Leukemia After Blinatumomab Treatment
CHEN Jingpei
CAI Wei
CHEN Zhi
LU Wenjie
SUN Ming
WANG Wei
YANG Li
Abstract：Objective To observe the peripheral blood CD19+B lymphocyte count,T lymphocyte cell surface pro-grammed death receptor 1(PD1)and tumor cell surface programmed death ligand 1(PD-L1)expression levels in children with refractory/recurrent B-acute lymphoblastic leukemia(BALL)after 7 days of Blinatumomab treatment.Methods The data of refractory/recurrent BALL children who treated with Blinatumomab in author's hospital from September 2021 to April 2024 were retrospectively analyzed.According to the 28-day minimal residual disease(MRD)results,the children were divided into MRD negative group(n=15)and MRD positive group(n=3).The counts of T and B lymphocytes in peripheral blood before and 7 d after treatment in two groups were detected and the levels of PD-1 and PD-L1 before treat-ment were detected.Results Compared with MRD positive group,the number of peripheral blood B lymphocytes in MRD negative group significantly decreased after 7 d of treatment(P＜0.001);the number of T and B lymphocytes in peripheral blood of MRD negative group significantly decreased after 7 d treatment than those before treatment(P＜0.001);the number of T and B lymphocytes in peripheral blood of children in MRD positive group were decreased af-ter 7 d of treatment compared with that before,but there were no statistical significance before and after treatment(P＞0.05).Before treatment,the expression levels of PD-1 and PD-L1 in MRD positive group were higher than those in MRD negative group,but there were no statistical significance between the two groups(P＞0.05).Conclusion The number of T and B lymphocytes in peripheral blood of children with negative MRD decreases more significantly after 7 d with Blinatumomab treatment.Before treatment,the expression of PD1/PD-L1 showed a higher trend in the MRD posi-tive group,but the difference was not statistically significant,suggesting that a higher level of PD-1/PD-L1 may affectthe therapeutic effect of Blinatumomab.
Keywords：BlinatumomabAcute B-acute lym-phoblastic leukemiaMinimal residual diseaseLymphocyte subgroupProgrammed death receptor 1Programmed death ligand 1
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1051-1054 )